Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Mölnlycke establishes first wound care manufacturing site in China
Changshu, China, and Gothenburg, Sweden. 5 November 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu, China. This strategic investment marks a milestone in Mölnlycke’s growth journey and the beginning of localised manufacturing in one of the world’s fastest-growing MedTech markets.
“Our site in Changshu marks another step forward in Mölnlycke’s ambition to manufacture products closer to where they are sold. It reflects our glocal approach, combining global standards with local relevance, and reinforces our commitment to sustainable growth, supply chain resilience and faster delivery of life-changing wound care solutions to caregivers and patients in China,” says Zlatko Rihter, CEO of Mölnlycke.
The manufacturing site, spanning 10,000 m2, will be set up in accordance with Mölnlycke’s global standards and is expected to initiate production of Mölnlycke wound care products at the end of 2026/early 2027. This strategic move will help future-proof Mölnlycke’s growth in China, laying the foundation for future capacity expansion and local job creation.
“This investment brings us closer to our customers in China and reinforces our mission to free patients and caregivers from the burden of wounds, with locally produced, high-quality solutions,” adds Jakob Sonnenberg, VP Greater China & India Wound Care at Mölnlycke.
The Changshu site strengthens Mölnlycke’s position in Asia and aligns with China’s growing demand for advanced, locally manufactured healthcare solutions.
For more information, please contact:
Latest news
Read all news-
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
-
5 million and growing: scaling Granudacyn® production in Salzburg
-
Mölnlycke Health Care announces Andreas Johansson as Interim Chief Financial Officer
Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect.
-
Mölnlycke® celebrates 100 million ProcedurePak® trays - advancing operating room efficiency worldwide
Gothenburg, Sweden. 27 January 2026. Mölnlycke Health Care, a global leader in Medtech, headquarted in Gothenburg, Sweden, is celebrating the production of 100 million ProcedurePak® trays at the company's production sites in the Czech Republic.
-
Mölnlycke donates patent to spark innovation in sustainable healthcare
Gothenburg, Sweden. 12 November 2025. Mölnlycke Health Care, a global leader in MedTech, is the first company to donate a patent to SKF’s groundbreaking digital platform, The Patent Bay – taking bold action to harness collaboration and accelerate innovation in sustainable healthcare.
-
Mölnlycke Health Care’s global headquarters ranked number one workplace in Sweden and top 20 globally in Leesman workplace experience survey
Gothenburg, Sweden, 15 October 2025 Mölnlycke® Health Care is proud to announce that its global headquarters have placed number one in Sweden, and top 20 globally, in the prestigious Leesman® Index, a benchmark survey measuring workplace experience across thousands of organisations worldwide.
-
Mölnlycke Health Care breaks ground on $135 million expansion of Wound Care manufacturing facility in Brunswick, Maine
Brunswick, Maine, USA and Gothenburg, Sweden. 23 September 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, today celebrates the groundbreaking of a major expansion to its wound care manufacturing capacity in Brunswick, Maine. This milestone marks the beginning of a $135 million investment aimed at significantly increasing Mölnlycke’s manufacturing capacity in the United States.
-
New study highlights the importance of double gloving with indicator systems
A new peer-reviewed study published in the Journal of Hospital Infection underscores the critical role of double gloving and indicator systems in reducing the risk of undetected glove breaches during surgery.
-
Mölnlycke Health Care AB: CEO, Zlatko Rihter, announces resignation, Guillaume Joucla appointed interim CEO
Tue, Mar 24, 2026 Today, it was announced that Zlatko Rihter, CEO of Mölnlycke Health Care, has informed the Board of Directors of his decision to resign. Following his decision, Guillaume Joucla, Chief Financial Officer, has been appointed interim CEO of Mölnlycke Health Care. Mölnlycke’s Board has initiated the recruitment process for a permanent CEO.